Watchlist Price Alert

Precision BioSciences Inc... (DTIL)

NASDAQ: DTIL · Real-Time Price · USD

5.15

-0.03 (-0.58%)

At close: May 08, 2025, 3:59 PM

5.25

1.94%

After-hours: May 08, 2025, 06:49 PM EDT

-0.58% (1D)

Bid	5.13
Market Cap	54.33M
Revenue (ttm)	68.7M
Net Income (ttm)	7.17M
EPS (ttm)	0.97
PE Ratio (ttm)	5.31
Forward PE	-0.95
Analyst	Buy

Ask	5.28
Volume	66,559
Avg. Volume (20D)	157,209
Open	5.02
Previous Close	5.18
Day's Range	5.01 - 5.21
52-Week Range	3.61 - 13.44
Beta	1.55

About DTIL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DTIL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DTIL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Precision BioSciences Inc. is scheduled to release its earnings on May 15, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+23.77%

Precision BioSciences shares are trading higher af... Unlock content with Pro Subscription

1 month ago

-11%

Precision BioSciences shares are trading lower following a Q4 EPS miss.

News

1 day ago · businesswire.com

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...

Precision BioSciences stock soars 24% as the FDA grants the Fast Track designation to its PBGENE-HBV gene therapy for potentially curing chronic hepatitis B.

3 weeks ago · businesswire.com

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

1 month ago · businesswire.com

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

1 month ago · zacks.com

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) came out with a quarterly loss of $3.20 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $3.35 per share a year ago.